Longevity & AgingArticle de rechercheAccès libre

High GDF-15 levels track with muscle loss and anemia in chronic kidney disease

In 268 non-dialysis CKD patients, higher GDF-15 was linked to muscle wasting and anemia. The design is cross-sectional, so causation is unproven.

mercredi 18 novembre 2026 1 vue
Publié dans J Nutr Health Aging
Glowing GDF-15 molecule binding a brainstem receptor, with a kidney and wasted muscle fibers in the background

Résumé

GDF-15 is a stress-response hormone that acts on the brainstem to suppress appetite and has been implicated in cancer cachexia. This cross-sectional study of 268 Taiwanese adults with stage 3-5 chronic kidney disease (not on dialysis) tested whether it tracks with wasting. Each natural-log increase in GDF-15 was associated with higher odds of muscle wasting (OR 2.93) and anemia (OR 3.45) after adjustment. Higher GDF-15 was also associated with higher all-cause mortality over a median 4.8 years (adjusted HR 2.60, wide CI). These are associations measured at one time point. The study cannot show that GDF-15 causes wasting or anemia in kidney disease, and no intervention was tested.

Résumé détaillé

Muscle wasting and anemia are common, damaging complications of chronic kidney disease (CKD). GDF-15 is a stress-induced cytokine that signals through the GFRAL receptor in the brainstem to reduce appetite and cause nausea. In cancer cachexia it is thought to drive weight and muscle loss, and blocking it has improved appetite and weight in patients. Levels run far higher in CKD, so it is a plausible, though untested, contributor to CKD cachexia.

This was a cross-sectional study at one Taiwanese hospital (2011-2012) of 268 adults with stage 3-5 CKD not on dialysis, recruited by convenience sampling. Plasma GDF-15 was measured by ELISA. Muscle mass was estimated by bioimpedance spectroscopy, not imaging. Muscle wasting used Asian sarcopenia criteria and anemia used KDIGO hemoglobin thresholds. Median GDF-15 was 2674 pg/mL (range 550-12,466).

Patients above the median GDF-15 were older and had lower lean tissue index, hemoglobin, albumin and eGFR. They also had higher NT-proBNP, proteinuria, IL-6 and TNF-α. In multivariable models, each natural-log increase in GDF-15 was associated with higher odds of muscle wasting (OR 2.93, 95% CI 1.23-6.97) and anemia (OR 3.45, 95% CI 1.09-10.91). Over a median 4.8 years there were 34 deaths, and higher GDF-15 was associated with mortality (adjusted HR 2.60, 95% CI 1.03-6.59). Sensitivity analyses, including a model without eGFR and a fully adjusted model, gave consistent results.

The mechanism is therefore supported by biological plausibility from other settings, but this study shows only association in people with CKD. It shows nothing about function, such as strength or physical performance, and nothing about whether lowering GDF-15 helps. Some findings were unexpected: diabetes was associated with lower odds of muscle wasting, and RAAS inhibitor use was independently protective, which suggests residual confounding or selection effects.

Caveats are substantial. The design cannot establish direction of effect, since wasting, anemia, inflammation and reduced renal clearance can all raise GDF-15. Confidence intervals are wide, with the lower bounds near 1. Stepwise selection was used and no correction was made for multiple comparisons, so the authors call the results hypothesis-generating. Bioimpedance is an indirect muscle measure, and the sample is a single-center, mostly male Taiwanese cohort. GDF-15 is worth watching as a marker and possible therapeutic target in CKD cachexia, but it is not yet a clinical tool.

Principales conclusions

  • Cross-sectional study of 268 non-dialysis stage 3-5 CKD patients; median plasma GDF-15 was 2674 pg/mL.
  • Each ln-unit rise in GDF-15 linked to higher odds of muscle wasting (OR 2.93, 95% CI 1.23-6.97) after adjustment.
  • Each ln-unit rise in GDF-15 linked to higher odds of anemia (OR 3.45, 95% CI 1.09-10.91); intervals are wide.
  • Higher GDF-15 was associated with all-cause mortality over 4.8 years (adjusted HR 2.60, 95% CI 1.03-6.59; 34 deaths).
  • No causal, strength/function or intervention data; diabetes and RAAS inhibitor use unexpectedly associated with lower wasting odds.

Méthodologie

Single-center cross-sectional study (Taipei Tzu Chi Hospital, 2011-2012) of 268 convenience-sampled non-dialysis stage 3-5 CKD patients. GDF-15 was measured by ELISA and muscle mass estimated by bioimpedance, with wasting and anemia defined by AWGS and KDIGO criteria. Analyses used stepwise multivariable regression and Cox models with sensitivity checks; there was no multiplicity correction.

Limites de l'étude

Cross-sectional design prevents inference about causality or direction, and reduced renal clearance, inflammation and heart strain may independently raise GDF-15. Muscle mass was estimated by bioimpedance, strength and function were not measured, and the single-center convenience sample used stepwise models without multiplicity correction, giving wide confidence intervals. The mortality analysis had few events (34).

Ce résumé vous a plu ?

Recevez les dernières recherches sur la longévité dans votre boîte de réception chaque semaine.

Saisissez votre e-mail pour vous abonner :